Alzamend Neuro Inc (ALZN)

$2.10 +0.06 (2.94%)
Market Cap 7.76M
Revenue (ttm) 0.00
Net Income (ttm) -4.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 813,624
Avg Vol 79,742
Day's Range N/A - N/A
Shares Out 3.81M
Stochastic %K 43%
Beta -0.25
Analysts Sell
Price Target $28.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
Manwiththeplan
Manwiththeplan Mar. 16 at 6:18 PM
$ALZN result will be good. 2 weeks to go!!
0 · Reply
AdvancedMomentumDivision
AdvancedMomentumDivision Mar. 16 at 5:58 PM
$ALZN popped up during my scans earlier today.
0 · Reply
Manwiththeplan
Manwiththeplan Mar. 16 at 4:27 PM
$CING oke took my profits here +100%. Target was 10. Could go much higher, but i am gone Good luck to all. I am going to $ALZN.
0 · Reply
BioAB
BioAB Mar. 16 at 4:12 PM
$ALZN pipe dream. This company will never get an Alzheimer’s drug. Avoid.
0 · Reply
StockDog2014
StockDog2014 Mar. 16 at 2:24 PM
$ALZN nice @topstockalerts was here! Let’s see some volume on this low float
0 · Reply
hiwatt
hiwatt Mar. 16 at 2:19 PM
$ALZN This kind of a cart before the horse PR which hopefully spurs some interest in the stock before the lithium in the brain results come out. It does show confidence in the program moving forward while we wait for Qmenta to finalize the data. On the surface, appears to be a smart move.
0 · Reply
topstockalerts
topstockalerts Mar. 16 at 2:14 PM
$ALZN This one tends to react strongly to company announcements. When news crosses and volume expands the chart can start trending quickly.
0 · Reply
StockDog2014
StockDog2014 Mar. 16 at 1:56 PM
$ALZN incoming pump?
0 · Reply
PennyStockTrader2
PennyStockTrader2 Mar. 16 at 1:47 PM
$ALZN so I am very curious what people think ... we are still getting results in the next two weeks, and this release, related, did not move the stock price (for the most part), why didnt it? Seems like the potential for a screaming buy, what am I missing?
1 · Reply
Noname66
Noname66 Mar. 16 at 1:00 PM
$ALZN How to find the link to vote. I am with Charles Schwab. Please help.
0 · Reply
Latest News on ALZN
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Mar 16, 2026, 8:00 AM EDT - 8 hours ago

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Nov 19, 2025, 8:00 AM EST - 4 months ago

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Jul 28, 2025, 8:00 AM EDT - 8 months ago

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Jul 23, 2025, 8:00 AM EDT - 8 months ago

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Jun 16, 2025, 8:00 AM EDT - 9 months ago

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 29, 2025, 8:00 AM EDT - 10 months ago

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 19, 2025, 8:00 AM EDT - 10 months ago

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

May 13, 2025, 8:00 AM EDT - 10 months ago

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 11 months ago

Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 7, 2025, 8:00 AM EDT - 11 months ago

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Mar 4, 2025, 8:10 AM EST - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Feb 25, 2025, 8:00 AM EST - 1 year ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Aug 19, 2024, 9:41 AM EDT - 1 year ago

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

May 7, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Apr 4, 2023, 6:30 AM EDT - 3 years ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 28, 2022, 6:30 AM EST - 3 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 22, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 21, 2022, 7:27 PM EST - 3 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Nov 1, 2022, 6:30 AM EDT - 3 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 22, 2022, 8:00 AM EDT - 3 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 17, 2021, 11:59 PM EST - 4 years ago

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

Dec 17, 2021, 9:54 AM EST - 4 years ago

Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate

See Why Alzamend Neuro Stock Is Rallying On Thursday

Sep 30, 2021, 1:45 PM EDT - 4 years ago

See Why Alzamend Neuro Stock Is Rallying On Thursday

Why Alzamend Neuro Shares Are Surging Higher Today

Sep 30, 2021, 11:54 AM EDT - 4 years ago

Why Alzamend Neuro Shares Are Surging Higher Today

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 30, 2021, 10:11 AM EDT - 4 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Sep 13, 2021, 6:30 AM EDT - 4 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Aug 4, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 30, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 28, 2021, 3:07 PM EDT - 5 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Jul 23, 2021, 7:20 AM EDT - 5 years ago

Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 23, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 5 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Jul 1, 2021, 11:23 AM EDT - 5 years ago

Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 1, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 17, 2021, 4:30 PM EDT - 5 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 16, 2021, 6:30 AM EDT - 5 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 5 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering

Manwiththeplan
Manwiththeplan Mar. 16 at 6:18 PM
$ALZN result will be good. 2 weeks to go!!
0 · Reply
AdvancedMomentumDivision
AdvancedMomentumDivision Mar. 16 at 5:58 PM
$ALZN popped up during my scans earlier today.
0 · Reply
Manwiththeplan
Manwiththeplan Mar. 16 at 4:27 PM
$CING oke took my profits here +100%. Target was 10. Could go much higher, but i am gone Good luck to all. I am going to $ALZN.
0 · Reply
BioAB
BioAB Mar. 16 at 4:12 PM
$ALZN pipe dream. This company will never get an Alzheimer’s drug. Avoid.
0 · Reply
StockDog2014
StockDog2014 Mar. 16 at 2:24 PM
$ALZN nice @topstockalerts was here! Let’s see some volume on this low float
0 · Reply
hiwatt
hiwatt Mar. 16 at 2:19 PM
$ALZN This kind of a cart before the horse PR which hopefully spurs some interest in the stock before the lithium in the brain results come out. It does show confidence in the program moving forward while we wait for Qmenta to finalize the data. On the surface, appears to be a smart move.
0 · Reply
topstockalerts
topstockalerts Mar. 16 at 2:14 PM
$ALZN This one tends to react strongly to company announcements. When news crosses and volume expands the chart can start trending quickly.
0 · Reply
StockDog2014
StockDog2014 Mar. 16 at 1:56 PM
$ALZN incoming pump?
0 · Reply
PennyStockTrader2
PennyStockTrader2 Mar. 16 at 1:47 PM
$ALZN so I am very curious what people think ... we are still getting results in the next two weeks, and this release, related, did not move the stock price (for the most part), why didnt it? Seems like the potential for a screaming buy, what am I missing?
1 · Reply
Noname66
Noname66 Mar. 16 at 1:00 PM
$ALZN How to find the link to vote. I am with Charles Schwab. Please help.
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 16 at 12:44 PM
$ALZN ALZN Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
0 · Reply
CoastalInvestments
CoastalInvestments Mar. 16 at 12:24 PM
$ALZN If you are a shareholder, VOTE. Retail shareholders CAN vote. Open your position through your brokerage to find a link to voting.
0 · Reply
hiwatt
hiwatt Mar. 16 at 12:16 PM
$ALZN Checking off the boxes to approval.
0 · Reply
StockNews_Live
StockNews_Live Mar. 16 at 12:04 PM
$ALZN 🎯 STOCK NEWS ALERT 💵 Price: $2.06 (-2.39%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Alzamend Neuro, Inc. initiated a Phase II clinical trial evaluating AL001 in patients diagnosed with bipolar disorder type 1. The trial is being conducted at Massachusetts General Hospital and… 📎 https://stocknews.live/news/ALZN/alzamend-neuro-initiates-phase-26091.html
0 · Reply
MindfulMonkey
MindfulMonkey Mar. 16 at 8:52 AM
$ALZN With news guaranteed by the end of this month, we know that the train is confirmed to be leaving the station within the next two weeks. Clinical trial results are anticipated to be very positive, so I look forward to the day the results are released. I've bought my ticket. LFG
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 14 at 4:33 AM
$ALZN RSI: 50.60, MACD: 0.0162 Vol: 0.15, MA20: 1.99, MA50: 2.08 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Biotechtrdr
Biotechtrdr Mar. 13 at 4:28 PM
$ALZN Low volume (tiny trades) pushing this down. weaker hands getting out, others anticipating positive news and hanging on for possible big gains. I think we get news this Tuesday. GLTA!
0 · Reply
MindfulMonkey
MindfulMonkey Mar. 13 at 9:46 AM
$IXHL disappointing. I was in this stock last summer from .21 to 1.7. If you're losing on this stock, come to $ALZN , phase 2 results confirmed to release by the end of this month. If the results are good, which it's looking like they will be, this will fly. Enjoy.
1 · Reply
Noname66
Noname66 Mar. 12 at 8:04 PM
$ALZN If phase 2 is pass. This will have 2 waves of trade. First will be $6 to $8. Back to close to $4. Second wave will be $10 to $14 before company dilute 2 millions shares to continue . I am not financial advisor . Just my own opinion. If news is not good. We are done. Lose everything.
1 · Reply
Manwiththeplan
Manwiththeplan Mar. 12 at 7:20 PM
$CING $ALZN is the next one. Study results this month
1 · Reply
Zipcash
Zipcash Mar. 10 at 4:34 PM
$ALZN That’s sounds Bullish news on the way!$$$
0 · Reply
Biotechtrdr
Biotechtrdr Mar. 9 at 5:24 PM
$ALZN Could be any day now. GLTA !
0 · Reply